Can responses to antiretroviral therapy be improved by therapeutic drug monitoring?

Clinical Infectious Diseases

Volumn 42, Issue 8, 2006, Pages 1197-1199

  Haas, David W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ANTIBIOTIC SENSITIVITY; CHILD; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONCENTRATION TARGETED DOSING; DOSE CALCULATION; DRUG DETERMINATION; DRUG EXPOSURE; DRUG INTERACTION; DRUG MONITORING; DRUG RESISTANCE; DRUG RESPONSE; DRUG SAFETY; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INTERINDIVIDUAL VARIATION; NOTE; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; THERAPEUTIC DRUG MONITORING; THERAPEUTIC INDEX; VARIANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG MONITORING; HIV PROTEASE INHIBITORS; HUMANS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33645796885     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/501464     Document Type: Note

References (12)

1. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002; 18: 825-34.
3. Fletcher CV, Acosta EP, Henry K, et al. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther 1998; 64:331-8.
4. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-9.
5. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14: 1333-9.
6. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17:1157-65.
7. Crommentuyn KM, Huitema AD, Brinkman K, Van der Ende ME, de Wolf F, Beijnen JH. Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study. J Acquir Immune Defic Syndr 2005; 39:249-50.
8. Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors - 12 week results. AIDS 2002; 16:2311-5.
9. Bossi P, Peytavin G, it-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 2004; 5:352-9.
10. Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006;42:1189-96 (in this issue).
11. Fraaij PL, Rakhmanina N, Burger DM, de GR. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit 2004; 26:122-6.
12. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400.